New myeloma drug combo aims to replace stem cell transplants

NCT ID NCT07428369

Terminated Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test a new drug called linvoseltamab combined with standard chemotherapy drugs (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if this combination, with or without a transplant, works better than the current standard treatment. However, the trial was withdrawn before any participants were enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: linvoseltamab (with bortezomib and lenalidomide)
What this could lead to: If successful, this could offer a new combination therapy for multiple myeloma that might reduce the need for stem cell transplants.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. The approach is still experimental and may not prove better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

More trials for these conditions

Other studies related to the condition(s) this trial covers.